通过CPG 7909增强小鼠对疟疾抗原AMA1的抗体产生需要CpG与抗原的物理结合。
Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen.
作者信息
Mullen Gregory E D, Aebig Joan A, Dobrescu Gelu, Rausch Kelly, Lambert Lynn, Long Carole A, Miles Aaron P, Saul Allan
机构信息
Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Rockville, MD 20852, USA.
出版信息
Vaccine. 2007 Jul 20;25(29):5343-7. doi: 10.1016/j.vaccine.2007.05.007. Epub 2007 May 25.
Abstract
CpG oligodeoxynucleotides are potent immunostimulants. In this study, CPG 7909 was formulated with the recombinant Plasmodium falciparum protein AMA1-C1 adsorbed to Alhydrogel (aluminum hydroxide) and used to immunize mice. Mice receiving free CPG 7909 in a separate same site injection to the AMA1-C1/Alhydrogel had the same antibody responses as mice receiving AMA1-C1/Alhydrogel alone. For mice immunized with CPG 7909 bound to the AMA1-C1/Alhydrogel formulation, there was a bell shaped CPG 7909 dose-response curve with the highest antibody response co-incident with the concentration of CPG 7909 that saturated binding to the Alhydrogel. At a higher CPG 7909 dose where 74% was unbound, there was no enhancement of response over AMA1-C1/Alhydrogel alone. Our results suggest that the adjuvant effects of CpGs are optimal when adsorbed to Alhydrogel and highlight the need for careful characterization of the vaccine formulation.
摘要
CpG 寡脱氧核苷酸是强效免疫刺激剂。在本研究中，将 CPG 7909 与吸附于氢氧化铝佐剂（Alhydrogel）的重组恶性疟原虫蛋白 AMA1-C1 一起配制，并用于免疫小鼠。在与 AMA1-C1/Alhydrogel 不同部位单独注射游离 CPG 7909 的小鼠，其抗体反应与单独接受 AMA1-C1/Alhydrogel 的小鼠相同。对于用与 AMA1-C1/Alhydrogel 制剂结合的 CPG 7909 免疫的小鼠，存在一条钟形的 CPG 7909 剂量反应曲线，最高抗体反应与饱和结合到 Alhydrogel 的 CPG 7909 浓度一致。在较高的 CPG 7909 剂量下，74%未结合，与单独使用 AMA1-C1/Alhydrogel 相比，反应没有增强。我们的结果表明，CpG 吸附到 Alhydrogel 时其佐剂效果最佳，并强调了对疫苗制剂进行仔细表征的必要性。
相似文献
1
Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen.通过CPG 7909增强小鼠对疟疾抗原AMA1的抗体产生需要CpG与抗原的物理结合。
Vaccine. 2007 Jul 20;25(29):5343-7. doi: 10.1016/j.vaccine.2007.05.007. Epub 2007 May 25.
2
Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria.AMA1-C1/氢氧化铝凝胶加CPG 7909的1期试验：一种用于恶性疟原虫疟疾的无性血液期疫苗。
PLoS One. 2008 Aug 13;3(8):e2940. doi: 10.1371/journal.pone.0002940.
3
Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide.使用CpG寡脱氧核苷酸增强对恶性疟原虫疟疾疫苗AMA1-C1/氢氧化铝凝胶的功能性抗体反应。
Vaccine. 2006 Mar 24;24(14):2497-505. doi: 10.1016/j.vaccine.2005.12.034. Epub 2006 Jan 4.
4
A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults.一项在半免疫的马里成年人中评估抗疟原虫 AMA1-C1/Alhydrogel + CPG 7909 疫苗的安全性和免疫原性的随机对照 1 期研究。
Vaccine. 2009 Dec 9;27(52):7292-8. doi: 10.1016/j.vaccine.2009.10.087. Epub 2009 Oct 27.
5
Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders.将CpG寡脱氧核苷酸添加到AMA1和Pfs25的重组铜绿假单胞菌外蛋白A偶联物中，可显著增加应答者的数量。
Vaccine. 2008 May 12;26(20):2521-7. doi: 10.1016/j.vaccine.2008.03.005. Epub 2008 Mar 27.
6
Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.顶端膜抗原1的1期临床试验：一种用于恶性疟原虫疟疾的无性血液期疫苗。
Infect Immun. 2005 Jun;73(6):3677-85. doi: 10.1128/IAI.73.6.3677-3685.2005.
7
Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.BSAM2/Alhydrogel®+CPG 7909 在无疟疾既往史的成年人中的 1 期研究，该疫苗针对恶性疟原虫疟疾的红内期。
PLoS One. 2012;7(10):e46094. doi: 10.1371/journal.pone.0046094. Epub 2012 Oct 4.
8
Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.在欧洲和非洲成年人中，用GLA-SE或氢氧化铝佐剂的重组恶性疟原虫AMA1-DiCo疟疾疫苗的安全性和免疫原性：一项1a/1b期随机双盲多中心试验。
Vaccine. 2017 Oct 27;35(45):6218-6227. doi: 10.1016/j.vaccine.2017.09.027. Epub 2017 Sep 22.
9
A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals.一项1期研究，针对候选血液期疟疾疫苗AMA1-C1/氢氧化铝凝胶与CPG 7909，采用两种不同配方和给药间隔。
Vaccine. 2009 Jun 24;27(31):4104-9. doi: 10.1016/j.vaccine.2009.04.077. Epub 2009 May 15.
10
Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.在感染志愿者中，蛋白加佐剂疫苗 AMA1-C1/Alhydrogel+CPG 7909 对疟原虫繁殖率的影响。
PLoS One. 2011;6(7):e22271. doi: 10.1371/journal.pone.0022271. Epub 2011 Jul 22.
引用本文的文献
1
Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants.含铝佐剂和 CpG 佐剂的 SARS-CoV-2 受体结合域（RBD）抗原的抗原-佐剂相互作用、稳定性和免疫原性特征。
Hum Vaccin Immunother. 2022 Nov 30;18(5):2079346. doi: 10.1080/21645515.2022.2079346. Epub 2022 Jun 6.
2
Evaluation of the AV7909 Anthrax Vaccine Toxicity in Sprague Dawley Rats Following Three Intramuscular Administrations.评价 AV7909 炭疽疫苗在 SD 大鼠肌肉注射 3 次后的毒性。
Int J Toxicol. 2021 Oct;40(5):442-452. doi: 10.1177/10915818211031239. Epub 2021 Jul 19.
3
Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want.优化疫苗中铝佐剂的利用：你可能会得偿所愿。
NPJ Vaccines. 2018 Oct 10;3:51. doi: 10.1038/s41541-018-0089-x. eCollection 2018.
4
Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach.铝氧水合凝胶吸附合成 TLR7/8 配体以增强疫苗佐剂活性：一种制剂方法。
J Control Release. 2016 Dec 28;244(Pt A):98-107. doi: 10.1016/j.jconrel.2016.11.011. Epub 2016 Nov 12.
5
Mechanism of immunopotentiation and safety of aluminum adjuvants.铝佐剂的免疫增强机制与安全性。
Front Immunol. 2013 Jan 10;3:406. doi: 10.3389/fimmu.2012.00406. eCollection 2012.
6
Adjuvants for Leishmania vaccines: from models to clinical application.利什曼病疫苗的佐剂：从模型到临床应用。
Front Immunol. 2012 Jun 11;3:144. doi: 10.3389/fimmu.2012.00144. eCollection 2012.
7
An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.一种与佐剂 Quil A 配制的 HIV-1 gp120 工程突变体促进了与 CD4 结合位点重叠的抗体反应的产生。
Vaccine. 2012 Jan 20;30(5):922-30. doi: 10.1016/j.vaccine.2011.11.089. Epub 2011 Dec 4.
8
TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity.TLR8 激动剂可刺激新募集的单核细胞衍生细胞成为有效的 APC，从而增强 HBsAg 的免疫原性。
Vaccine. 2010 Aug 31;28(38):6273-81. doi: 10.1016/j.vaccine.2010.06.117. Epub 2010 Jul 15.
9
Mimetics of hormetic agents: stress-resistance triggers.激动剂模拟物：应激抵抗触发物。
Dose Response. 2010 Jan 6;8(1):97-121. doi: 10.2203/dose-response.09-025.Sonneborn.
10
A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals.一项1期研究，针对候选血液期疟疾疫苗AMA1-C1/氢氧化铝凝胶与CPG 7909，采用两种不同配方和给药间隔。
Vaccine. 2009 Jun 24;27(31):4104-9. doi: 10.1016/j.vaccine.2009.04.077. Epub 2009 May 15.
本文引用的文献
1
Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide.使用CpG寡脱氧核苷酸增强对恶性疟原虫疟疾疫苗AMA1-C1/氢氧化铝凝胶的功能性抗体反应。
Vaccine. 2006 Mar 24;24(14):2497-505. doi: 10.1016/j.vaccine.2005.12.034. Epub 2006 Jan 4.
2
CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.CPG 7909佐剂可提高接受抗逆转录病毒治疗的HIV感染成人的乙肝病毒疫苗血清保护率。
AIDS. 2005 Sep 23;19(14):1473-9. doi: 10.1097/01.aids.0000183514.37513.d2.
3
Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.顶端膜抗原1的1期临床试验：一种用于恶性疟原虫疟疾的无性血液期疫苗。
Infect Immun. 2005 Jun;73(6):3677-85. doi: 10.1128/IAI.73.6.3677-3685.2005.
4
Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations.Montanide ISA 720疫苗：乳剂的质量控制、配方抗原的稳定性以及疫苗配方的比较免疫原性。
Vaccine. 2005 Mar 31;23(19):2530-9. doi: 10.1016/j.vaccine.2004.08.049.
5
CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study.CPG 7909，一种免疫刺激型Toll样受体9激动剂寡脱氧核苷酸，作为健康成年人中乙肝疫苗（安在时）的佐剂：一项双盲I/II期研究。
J Clin Immunol. 2004 Nov;24(6):693-701. doi: 10.1007/s10875-004-6244-3.
6
Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response.CpG寡核苷酸的联合使用可增强人抗乙肝疫苗应答的晚期亲和力成熟过程。
Vaccine. 2004 Dec 16;23(5):615-22. doi: 10.1016/j.vaccine.2004.07.014.
7
Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine.CPG 7909注射液作为Fluarix流感疫苗佐剂的安全性和免疫原性。
Vaccine. 2004 Aug 13;22(23-24):3136-43. doi: 10.1016/j.vaccine.2004.01.058.
8
Use of CpG oligodeoxynucleotides as immune adjuvants.将CpG寡脱氧核苷酸用作免疫佐剂。
Immunol Rev. 2004 Jun;199:201-16. doi: 10.1111/j.0105-2896.2004.00148.x.
9
Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1.恶性疟原虫42千道尔顿C末端裂殖子表面蛋白1的细菌表达及重折叠产物的生化与免疫学特性分析
Infect Immun. 2003 Dec;71(12):6766-74. doi: 10.1128/IAI.71.12.6766-6774.2003.
10
In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.重组恶性疟原虫顶端膜抗原1（AMA1）的体外研究：AMA1疫苗的生产与活性以及多等位基因反应的产生
Infect Immun. 2002 Dec;70(12):6948-60. doi: 10.1128/IAI.70.12.6948-6960.2002.
Zotero 插件